When was Corcept founded?

Corcept was founded in 1998 and raised its 1st funding round 8 years after it was founded.

Where is Corcept located?

Corcept is headquartered in Menlo Park, United States.

How many employees does Corcept have?

As of Sep 30, 2026, the latest employee count at Corcept is 804.

Is Corcept a funded company?

Corcept is a funded company, having raised an undisclosed amount across 6 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Nov 15, 2006.

When was the latest funding round of Corcept?

Corcept's latest funding was a $***** Post IPO round on 2011, with participation from 1 investor.

What is the annual revenue of Corcept?

Annual revenue of Corcept is between $500M and $1B as on Dec 31, 2025

Where does Corcept rank among its competitors?

Corcept ranks 3rd amongst 43 active competitors, of which 11 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Sernova, which secured $345K in Oct, 2025.

Who are the top competitors of Corcept?

Corcept's top competitors include Rhythm Pharmaceuticals, MannKind Corp and Genfit. Among them, Sernova secured the most recent funding round in October, 2025.

Corcept - 2026 Company Profile, Team, Funding, Competitors & Financials

Corcept is a public company based in Menlo Park (United States), founded in 1998 by Joe Belanoff. It operates as a Developer of cortisol modulators for the treatment of various diseases. Corcept has raised an undisclosed amount in funding. The company has 43 active competitors, including 11 funded and 19 that have exited. Its top competitors include companies like Rhythm Pharmaceuticals, MannKind Corp and Genfit.

Company Details

Developer of cortisol modulators for the treatment of various diseases. The company focuses on the discovery and development of drugs that modulate the effects of cortisol that target glucocorticoid receptor (GR) antagonists to treat a variety of endocrine, metabolic, oncologic, psychiatric, and ophthalmologic diseases.

Website: corcept.com
Social

Key Metrics

Founded Year

1998

Location

Menlo Park, United States

Stage

Public

Latest Funding Round

Post IPO, 2011, $*****

Investors

Longitude Capital & 8 more

Ranked

3^rd among 43 active competitors

Annual Revenue

$500M - $1B as on Dec 31, 2025

Employee Count

804 as on Sep 30, 2026

Similar Companies

Rhythm Pharmaceuticals & 59 more

Exit Details

Public

View Corcept's full profile

Corcept is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Corcept Therapeutics Inc CIN: 1088856 , United States, Active	May 12, 1998	$500M - $1B (As on Dec 31, 2025)	-	-
CORCEPT THERAPEUTICS INCORPORATION CIN: 77-0487658 , United States, Active	Dec 31, 1997	-	352 (As on Dec 31, 2023)	-

Corcept got listed on Jan 05, 2004.

Click here to take a look at Corcept's IPO in detail

Corcept has raised funding over 6 rounds. Its first funding round was on Nov 15, 2006. Its latest funding round was a Post IPO round on 2011 for $*****. 1 investor participated in its latest round. Corcept has 9 institutional investors.

Here is the list of recent funding rounds of Corcept:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
2011	4895	Post IPO	7361	7045	5612	7290
Apr 30, 2010	5849109	Post IPO	1872929	5026751	2039272	7505667
Oct 13, 2009	2582028	Post IPO	3865779	3707261	6745477	2273621

Access funding benchmarks and valuations. Sign up today!

View details of Corcept's funding rounds and investors

The founders of Corcept is Joe Belanoff.

Here are the details of Corcept's key team members:

Joe Belanoff: Co-Founder & CEO of Corcept.

View details of Corcept's Founder profiles and Board Members

Corcept's employee count trend

Corcept has 804 employees as of Sep 26. Here is Corcept's employee count trend over the years:

Uncover Corcept's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Corcept include Rhythm Pharmaceuticals, MannKind Corp and Genfit. Here is the list of Top 10 competitors of Corcept, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 9 others	70/100
2nd	MannKind Corp 1991, Los Angeles (United States), Public	Developer of small-molecule drugs	$50M	Colt Ventures, Ignite 500 & 1 others	70/100
3rd	Corcept 1998, Menlo Park (United States), Public	Developer of cortisol modulators for the treatment of various diseases	-	Longitude Capital, Cornerstone Capital & 7 others	69/100
4th	Genfit 1999, Loos (France), Public	Therapeutics for cardiometabolic and neurodegenerative diseases.	-	Eiffel Investment Group, Ridgeback Capital Management ... & 2 others	59/100
5th	89bio 2018, San Francisco (United States), Acquired	Developer of therapies for treating nonalcoholic steatohepatitis and other liver and metabolic disorders	$60M	Longitude Capital, Orbimed & 3 others	58/100
6th	Sernova 1998, London (Canada), Public	Regenerative medicine to deliver proteins and hormones for disease treatment	-	National Research Council Canada, Europa & 1 others	57/100
7th	Verdiva Bio 2024, London (United Kingdom), Series A	Developer of oral and injectable peptide therapies for metabolic diseases	$411M	General Atlantic, Forbion & 5 others	56/100
8th	OptiBiotix Health 2012, York (United Kingdom), Public	Developer of microbial strains for the treatment of human metabolic diseases	-	Seneca EIS Portfolio Fund, Mercia & 2 others	55/100
9th	ViaCyte 1999, San Diego (United States), Acquired	Developer of cell therapy for the treatment of diabetes	$389M	Bain Capital Life Sciences, Sanderling Ventures ... & 21 others	54/100
10th	PhaseBio Pharmaceuticals 2002, Malvern (United States), Public	Developer of novel drugs to treat metabolic and cardiopulmonary disorders	$152M	Rock Springs Capital, AstraZeneca & 12 others	54/100